BioMarin Stock: Approval For Hemophilia Gene Treatment Likely

Gavel with law book

simonkr/iStock through Getty Images

Financial Investment Summary

BioMarin ( NASDAQ: BMRN) is a $17bn market cap (at the time of composing) business phase pharmaceutical business that is frequently discussed as an appealing target for a bigger Pharma taking part in M&A.

The uncommon

chart

BioMarin profits by item Q1 ’23 (BioMarin Q1 ’23 10-Q submission)

chart

Biomarin FY23 assistance (Biomarin profits discussion)

Like this post? Please share to your friends:
Leave a Reply

;-) :| :x :twisted: :smile: :shock: :sad: :roll: :razz: :oops: :o :mrgreen: :lol: :idea: :grin: :evil: :cry: :cool: :arrow: :???: :?: :!: